Clinical trials: CtDNA
Neoplasms, Unknown Primary, Cancer
Molecular Analysis of Blood Samples in Standardized Cancer Care Referrals for SCAN and CUP
Patients with suspected cancer (SCAN) and cancer of unknown primary tumor (CUP) are vulnerable because the investigation is difficult and expensive and have poor prognosis because few effective established curative treatments are…
- Trial name
- NCT04025970
- Testing
- Circulating tumor cell and circulating tumor DNA test
- Where
- Sweden
- Volunteers
- 200 people
- Sponsor
- Christer Ericsson
Colon Adenocarcinoma, Stage IIA Colon Cancer AJCC v8
Circulating Tumor DNA Testing in Predicting Treatment for Patients With Stage IIA Colon Cancer After Surgery
This phase II/III trial studies how well circulating tumor deoxyribonucleic acid (ctDNA) testing in the blood works in predicting treatment for patients with stage IIA colon cancer after surgery.
- Trial name
- NCT04068103
- Testing
- Capecitabine, Fluorouracil, Leucovorin
- Where
- 957 sites in United States, Canada and 1 more
- Volunteers
- 635 people
- Sponsor
- NRG Oncology
Hepatobiliary Cancer, Pancreatic Cancer
Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers
This is a prospective pilot protocol investigating whether ctDNA detection be improved by sampling the cancer draining vein versus the standard practice of sampling from a peripheral vein in patients who are undergoing biopsies…
- Conditions
- Hepatobiliary Cancer, Pancreatic Cancer, Hepatocellular Carcinoma, Cholangiocarcinoma
- Trial name
- NCT05497531
- Testing
- ctDNA Blood Collection
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of California, Irvine
Non Small Cell Lung Cancer
Recurrence Monitoring in NSCLC Using Circulating Tumor DNA
This research study is investigating the role of cell free tumor DNA profiling in determining disease relapse and/or progression for patients with advanced NSCLC.
- Trial name
- NCT03878537
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Scripps Translational Science Institute
Sarcoma
Recognition of Circulating Tumor DNA in Soft Tissue Sarcoma
A tissue biopsy is currently the only clinical test or procedure that is able to confirm the initial diagnosis of soft tissue or metastatic sarcoma and evaluate its progress during treatment.
- Trial name
- NCT03896620
- Testing
- Preoperative RT, Postoperative RT, Chemotherapy
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Medical College of Wisconsin
Leiomyosarcoma
Localized Leiomyosarcoma Biomarker Protocol
Leiomyosarcoma (LMS) is one of the more common soft tissue sarcomas (STS). Patients presenting with large, high-grade, localized LMS are at significant risk of developing metastasis following curative surgery.
- Trial name
- NCT04925089
- Testing
- Blood and Tissue collection
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- University of Michigan Rogel Cancer Center
Colorectal Cancer
TAS-102 With or Without Celecoxib in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy
To measure the level of circulating tumor DNA (ctDNA) in the blood of colorectal cancer patients after 6 months of receiving TAS-102 therapy. ctDNA is genetic material from tumor cells that can be found and measured in the blood.
- Trial name
- NCT05343013
- Testing
- TAS-102
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- M.D. Anderson Cancer Center
Metastatic Non-small Cell Lung Cancer
Early Assessment of Response to Treatment of Metastatic LUng Tumors Based on CIrculating Tumor DNA
In patients with locally advanced or metastatic tumors, first-line therapeutic management is based on the use of targeted therapies (EGFR, BRAF ALK and ROS1 inhibitors), immunotherapies (anti-PD1/ anti-PDL1-antibodies or…
- Trial name
- ELUCID (NCT03926260)
- Testing
- ctDNA analysis
- Where
- 2 sites in France
- Volunteers
- 100 people
- Sponsor
- Centre Hospitalier Departemental Vendee
Breast Cancer, TNBC - Triple-Negative Breast Cancer
Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies
For patients with breast cancer, it's important to find any remaining cancer cells after they've had their main treatment. Even a few cells, called minimal residual disease (MRD), can lead to the cancer coming back later.
- Conditions
- Breast Cancer, TNBC - Triple-Negative Breast Cancer, HR Positive/HER-2 Negative Breast Cancer, HER2 + Breast Cancer
- Trial name
- GEMINI Breast (NCT07211178)
- Testing
- There are no interventions in this observational study.
- Where
- 16 sites in United States
- Volunteers
- 900 people
- Sponsor
- Tempus AI
Multiple Primary Cancers
Value of ctDNA in the Treatment of Multiple Primary Cancers
This trial is a single-center, prospective, exploratory study.The objective is to study the peripheral blood circulating tumor DNA (CT-DNA) gene profile of patients with multiple primary tumors (MPC) and to evaluate the…
- Trial name
- NCT05164510
- Testing
- ct-DNA guided therapy
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Fudan University
Endometrial Cancer
Signatera Assessment in Early-Stage Endometrial Cancer
The goal of this clinical trial is to assess if circulating tumor DNA can guide adjuvant selection in high-intermediate risk early-stage endometrial cancer.
- Trial name
- SIGNAL-EMC 101 (NCT07339384)
- Testing
- Signatera Genome ultra-sensitive ctDNA blood test
- Where
- 12 sites in United States
- Volunteers
- 1,010 people
- Sponsor
- Natera, Inc.
Colorectal Cancer
Circulating Tumor DNA (ctDNA) as a Predictive Biomarker for Immunotherapy in Advanced or Locally Advanced dMMR/MSI-H Colorectal Patients
dMMR/MSI-H colorectal cancer patients are the dominant population of immunotherapy/neoadjuvant immunotherapy, but imaging evaluation of immunotherapy efficacy is insufficient.
- Trial name
- NCT06098560
- Where
- 2 sites in China
- Volunteers
- 60 people
- Sponsor
- Geneplus-Beijing Co. Ltd.
Lung Cancer, Non Small Cell Lung Cancer
Trial of ctDNA of Guidance to Determine PostOperative Radiation Therapy
Primary Objective: Evaluate the role of ctDNA positivity in decision making for postoperative therapy for non-small cell lung cancer.
- Conditions
- Lung Cancer, Non Small Cell Lung Cancer, Lung Cancer Recurrent
- Trial name
- PORT (NCT06979661)
- Testing
- Haystack™ ctDNA Assay
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Rutgers, The State University of New Jersey
Esophageal Cancer, Gastric Cancer
Clinical Utility of Circulating Tumor DNA in Gastro-Esophageal Cancer
This is a prospective cohort study designed to evaluate the treatment effect as well as predictive and prognostic factors with special emphasis on the clinical utility of ctDNA in plasma in patients with gastroesophageal cancer.
- Trial name
- CURE (NCT04576858)
- Testing
- Circulating tumor DNA
- Where
- Denmark
- Volunteers
- 1,950 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Stage III NSCLC, Surgery
Induction Lorlatinib in Stage III Non-small Cell Lung Cancer
A prospective, single-arm, open-label phase 2 study that evaluates the efficacy and safety of induction Lorlatinib in stage III non-small cell lung cancer and explores the clinical feasibility of dynamic ctDNA and…
- Trial name
- NCT05740943
- Testing
- Lorlatinib
- Where
- 4 sites in China
- Volunteers
- 48 people
- Sponsor
- Guangdong Provincial People's Hospital
NSCLC Stage IIIB, NSCLC Stage IV
Additional Chemotherapy for EGFRm Patients with the Continued Presence of Plasma CtDNA EGFRm At Week 3 After Start of Osimertinib 1st-line Treatment (PACE-LUNG)
PACE is a prospective multicenter single-arm investigator-initiated phase II trial that examines the value of a treatment escalation strategy by the addition of platinum-based doublet chemotherapy to osimertinib in patients with…
- Trial name
- NCT05281406
- Testing
- Osimertinib, Pemetrexed, Cisplatin
- Where
- 16 sites in Germany
- Volunteers
- 50 people
- Sponsor
- Goethe University
ALK Positive Non-small Cell Lung Cancer
Lorlatinib Plus Sacituzumab Tirumotecan With Peripheral ctDNA Guidance as First-Line Therapy for ALK Fusion-Positive NSCLC
This investigator-initiated, open-label, prospective Phase II clinical trial, planned to take place across multiple centers in China.
- Trial name
- NCT07750704
- Testing
- Lorlatinib, sacituzumab tirumotecan plus lorlatinib
- Where
- China
- Volunteers
- 153 people
- Sponsor
- Guangdong Association of Clinical Trials
ER-positive, HER2-negative Breast Cancer, Breast Cancer Stage I
Capecitabine in ER+/HER2-negative Breast Cancer
This is a Phase 2 study for patients with resected Stage I-III HR+/HER2-negative breast cancer with detected molecular residual disease (MRD+) following standard neo/adjuvant and locoregional therapy delivered with curative…
- Conditions
- ER-positive, HER2-negative Breast Cancer, Breast Cancer Stage I, Breast Cancer Stage II, Breast Cancer Stage III
- Trial name
- NCT07631052
- Testing
- Capecitabine
- Where
- Canada
- Volunteers
- 15 people
- Sponsor
- University Health Network, Toronto
Breast Cancer, Lymph Node Metastasis
Molecular Residual Disease Assessment in a Representative Diverse Population of Patients With Early-stage Breast Cancer
The purpose of this study is to determine how circulating tumor DNA (ctDNA), a sign of minimal residual disease (MRD), is detectable after surgery in patients with early HR+/HER2- breast cancer that has spread to 1-3 lymph nodes.
- Trial name
- NCT07025785
- Testing
- Circulating tumor DNA
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Lung Neoplasms
Practical Usability of EGFR Mutation Detection in ctDNA From Resectable NSCLC
The aim of the study is to assess the practical usability of EGFR mutation detection in ctDNA from early NSCLC.
- Trial name
- NCT04922073
- Where
- South Korea
- Volunteers
- 150 people
- Sponsor
- Samsung Medical Center